BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim KR, Moon HE, Kim KW. Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl). 2002;80:703-714. [PMID: 12436347 DOI: 10.1007/s00109-002-0380-0] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Fujino T, Murakami K, Ozawa I, Minegishi Y, Kashimura R, Akita T, Saitou S, Atsumi T, Sato T, Ando K, Hara S, Kikugawa K, Hayakawa M. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway: Hypoxia downregulates FXR via p38 MAPK. FEBS Journal 2009;276:1319-32. [DOI: 10.1111/j.1742-4658.2009.06867.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
2 Guo X, Chen Y, Fang W, Yang W, Shi L, Zhu R. Metastasis associated protein 1 correlates with Hypoxia inducible-factor 1 alpha expression and lymphangiogenesis in esophageal cancer: Metastasis associated protein 1. Thoracic Cancer 2013;4:312-7. [DOI: 10.1111/1759-7714.12024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Kelm JM, Diaz Sanchez-Bustamante C, Ehler E, Hoerstrup SP, Djonov V, Ittner L, Fussenegger M. VEGF profiling and angiogenesis in human microtissues. J Biotechnol 2005;118:213-29. [PMID: 15951040 DOI: 10.1016/j.jbiotec.2005.03.016] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 4.0] [Reference Citation Analysis]
4 Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G. Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle. 2012;11:2843-2855. [PMID: 22801548 DOI: 10.4161/cc.21193] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 8.5] [Reference Citation Analysis]
5 Corradini SG, Morini S, Liguori F, Carotti S, Muda AO, Burza MA, Siciliano M, Molinaro A, Cantafora A, Blotta I, Merli M, Berloco P, Rossi M, Attili AF, Gaudio E. Differential vascular endothelial growth factor A protein expression between small hepatocellular carcinoma and cirrhosis correlates with serum vascular endothelial growth factor A and alpha-fetoprotein. Liver Int 2009;29:103-12. [PMID: 18544126 DOI: 10.1111/j.1478-3231.2008.01781.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
6 Hsu MH, Wu SC, Pao KC, Unlu I, Gnabre JN, Mold DE, Huang RC, Hwu JR. Hepatocellular carcinoma targeting agents: conjugates of nitroimidazoles with trimethyl nordihydroguaiaretic acid. ChemMedChem 2014;9:1030-7. [PMID: 24648164 DOI: 10.1002/cmdc.201300521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Sibold S, Roh V, Keogh A, Studer P, Tiffon C, Angst E, Vorburger SA, Weimann R, Candinas D, Stroka D. Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for its membrane localization in human hepatocellular carcinoma. FEBS Letters 2007;581:989-94. [DOI: 10.1016/j.febslet.2007.01.080] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
8 Amarapurkar AD, Amarapurkar DN, Vibhav, Patel ND. Angiogenesis in chronic liver disease. Annals of Hepatology 2007;6:170-3. [DOI: 10.1016/s1665-2681(19)31924-6] [Cited by in Crossref: 27] [Article Influence: 1.8] [Reference Citation Analysis]
9 Gou L, Wang W, Tong A, Yao Y, Zhou Y, Yi C, Yang J. Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma. J Mol Med (Berl) 2011;89:817-27. [PMID: 21475975 DOI: 10.1007/s00109-011-0753-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
10 Lee TY, Leu YL, Wen CK. Modulation of HIF-1α and STAT3 signaling contributes to anti-angiogenic effect of YC-1 in mice with liver fibrosis. Oncotarget 2017;8:86206-16. [PMID: 29156788 DOI: 10.18632/oncotarget.21039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
11 Browne M, Stellmach V, Cornwell M, Chung C, Doll JA, Lee EJ, Jameson JL, Reynolds M, Superina RA, Abramson LP, Crawford SE. Gene transfer of pigment epithelium-derived factor suppresses tumor growth and angiogenesis in a hepatoblastoma xenograft model. Pediatr Res 2006;60:282-7. [PMID: 16857775 DOI: 10.1203/01.pdr.0000232789.86632.91] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
12 Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma. Radiographics 2005;25 Suppl 1:S3-23. [PMID: 16227495 DOI: 10.1148/rg.25si055507] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
13 Maegdefrau U, Amann T, Winklmeier A, Braig S, Schubert T, Weiss TS, Schardt K, Warnecke C, Hellerbrand C, Bosserhoff AK. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol. 2009;218:520-529. [PMID: 19431154 DOI: 10.1002/path.2563] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
14 Sun HX, Xu Y, Yang XR, Wang WM, Bai H, Shi RY, Nayar SK, Devbhandari RP, He YZ, Zhu QF. Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway. Hepatology. 2013;57:1088-1097. [PMID: 23212661 DOI: 10.1002/hep.26188] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
15 Ha BY, Ahmed A, Sze DY, Razavi MK, Simpson N, Keeffe EB, Nguyen MH. Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Aliment Pharmacol Ther 2007;26:839-46. [PMID: 17767468 DOI: 10.1111/j.1365-2036.2007.03424.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
16 Ma J, Zhang L, Zhang J, Liu M, Wei L, Shen T, Ma C, Wang Y, Chen Y, Zhu D. 15-Lipoxygenase-1/15-hydroxyeicosatetraenoic acid promotes hepatocellular cancer cells growth through protein kinase B and heat shock protein 90 complex activation. The International Journal of Biochemistry & Cell Biology 2013;45:1031-41. [DOI: 10.1016/j.biocel.2013.02.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sun X, Krissansen GW, Fung PW, Xu S, Shi J, Man K, Fan ST, Xu R. Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. Int J Cancer. 2005;113:670-677. [PMID: 15472906 DOI: 10.1002/ijc.20624] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
18 Park SC, Yoon JH, Lee JH, Yu SJ, Myung SJ, Kim W, Gwak GY, Lee SH, Lee SM, Jang JJ, Suh KS, Lee HS. Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. Cancer Lett 2008;271:314-22. [PMID: 18657357 DOI: 10.1016/j.canlet.2008.06.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
19 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Frenette C, Gish RG. Hepatocellular carcinoma: molecular and genomic guideline for the clinician. Clin Liver Dis 2011;15:307-21, vii-x. [PMID: 21689615 DOI: 10.1016/j.cld.2011.03.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
21 Cariello NF, Romach EH, Colton HM, Ni H, Yoon L, Falls JG, Casey W, Creech D, Anderson SP, Benavides GR, Hoivik DJ, Brown R, Miller RT. Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. Toxicol Sci 2005;88:250-64. [PMID: 16081524 DOI: 10.1093/toxsci/kfi273] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 3.1] [Reference Citation Analysis]
22 Daskalow K, Pfander D, Weichert W, Rohwer N, Thelen A, Neuhaus P, Jonas S, Wiedenmann B, Benckert C, Cramer T. Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochem Cell Biol. 2009;132:21-31. [PMID: 19350262 DOI: 10.1007/s00418-009-0590-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
23 Daskalow K, Rohwer N, Raskopf E, Dupuy E, Kühl A, Loddenkemper C, Wiedenmann B, Schmitz V, Cramer T. Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med (Berl). 2010;88:817-827. [PMID: 20383692 DOI: 10.1007/s00109-010-0623-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
24 Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. BMC Cancer 2020;20:1001. [PMID: 33059615 DOI: 10.1186/s12885-020-07471-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Dou P, Zhang D, Cheng Z, Zhou G, Zhang L. PKIB promotes cell proliferation and the invasion-metastasis cascade through the PI3K/Akt pathway in NSCLC cells. Exp Biol Med (Maywood) 2016;241:1911-8. [PMID: 27325557 DOI: 10.1177/1535370216655908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
26 McKillop IH, Schrum LW, Thompson KJ. Role of alcohol in the development and progression of hepatocellular carcinoma. Hepat Oncol 2016;3:29-43. [PMID: 30191025 DOI: 10.2217/hep.15.40] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kazmi I, Al-Abbasi FA, Afzal M, Altayb HN, Nadeem MS, Gupta G. Formulation and Evaluation of Kaempferol Loaded Nanoparticles against Experimentally Induced Hepatocellular Carcinoma: In Vitro and In Vivo Studies. Pharmaceutics 2021;13:2086. [PMID: 34959368 DOI: 10.3390/pharmaceutics13122086] [Reference Citation Analysis]
28 Xiao L, Yue X, Ming X, Xu L, Ding M, Xu J, Liu Q. The integrin-linked kinase gene up-regulated by hypoxia plays its pro-survival role in colorectal cancer cells. J Recept Signal Transduct Res. 2014;34:64-72. [PMID: 24299190 DOI: 10.3109/10799893.2013.862271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
29 Mamori S, Asakura T, Ohkawa K, Tajiri H. Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition. World J Gastroenterol 2007; 13(40): 5306-5311 [PMID: 17879398 DOI: 10.3748/wjg.v13.i40.5306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
30 Casadaban L, Parvinian A, Tzvetanov I, Jeon H, Oberholzer J, Benedetti E, Bui J, Gaba R. Unconventional Extrahepatic Neovascularization After Transplant Hepatic Artery Thrombosis: A Case Report. Transplantation Proceedings 2013;45:2841-4. [DOI: 10.1016/j.transproceed.2013.03.048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
31 Pocha C, Xie C. Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? Transl Gastroenterol Hepatol 2019;4:72. [PMID: 31728429 DOI: 10.21037/tgh.2019.09.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
32 Aiad HAS, Kandil MAH, Samaka RM, Sultan MM, Badr MT, Nada GEM. The role of CK7, Ki-67, CD34 and vimentin in the differentiation between biliary atresia and idiopathic neonatal hepatitis in Egyptian cholestatic neonates: CK7, KI-67, CD34, VIMENTIN IN DIAGNOSIS OF BA AND INH. APMIS 2012;120:529-38. [DOI: 10.1111/j.1600-0463.2011.02859.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
33 Zhou C, Liu J, Tang Y, Zhu G, Zheng M, Jiang J, Yang J, Liang X. Coexpression of hypoxia-inducible factor-2α, TWIST2, and SIP1 may correlate with invasion and metastasis of salivary adenoid cystic carcinoma. J Oral Pathol Med. 2012;41:424-431. [PMID: 22103974 DOI: 10.1111/j.1600-0714.2011.01114.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
34 Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22:1178-82. [PMID: 17559361 DOI: 10.1111/j.1440-1746.2007.04997.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 8.8] [Reference Citation Analysis]
35 Shim JH, Chung Y, Kim JA, Lee D, Kim KM, Lim Y, Lee HC, Lee YS, Yu E, Lee YJ. Clinical Implications of Arrest-Defective Protein 1 Expression in Hepatocellular Carcinoma: A Novel Predictor of Microvascular Invasion. Dig Dis 2012;30:603-8. [DOI: 10.1159/000343090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
36 Abe M, Koga H, Yoshida T, Masuda H, Iwamoto H, Sakata M, Hanada S, Nakamura T, Taniguchi E, Kawaguchi T. Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-κB/hypoxia-inducible factor-1α axis under hypoxic conditions. Hepatol Res. 2012;42:591-600. [PMID: 22221855 DOI: 10.1111/j.1872-034x.2011.00953.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
37 Valletta D, Czech B, Spruss T, Ikenberg K, Wild P, Hartmann A, Weiss TS, Oefner PJ, Müller M, Bosserhoff A, Hellerbrand C. Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma. Carcinogenesis 2014;35:1407-15. [DOI: 10.1093/carcin/bgu054] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
38 El-swefy S, Hassanen SI. Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats. Annals of Hepatology 2009;8:41-9. [DOI: 10.1016/s1665-2681(19)31810-1] [Cited by in Crossref: 27] [Article Influence: 2.1] [Reference Citation Analysis]
39 Meng P, Zhang YF, Zhang W, Chen X, Xu T, Hu S, Liang X, Feng M, Yang X, Ho M. Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells. Sci Rep 2021;11:40. [PMID: 33420124 DOI: 10.1038/s41598-020-79524-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 van Malenstein H, Verslype C, Windmolders P, van Eijsden R, Nevens F, van Pelt J. Characterization of a cell culture model for clinically aggressive hepatocellular carcinoma induced by chronic hypoxia. Cancer Lett. 2012;315:178-188. [PMID: 22088439 DOI: 10.1016/j.canlet.2011.09.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
41 O'Brien HD. Cranial arterial patterns of the alpaca (Camelidae: Vicugna pacos). R Soc Open Sci 2017;4:160967. [PMID: 28405385 DOI: 10.1098/rsos.160967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
42 Chen YW, Pan HB, Tseng HH, Hung YT, Huang JS, Chou CP. Assessment of blood flow in hepatocellular carcinoma: correlations of computed tomography perfusion imaging and circulating angiogenic factors. Int J Mol Sci. 2013;14:17536-17552. [PMID: 23985826 DOI: 10.3390/ijms140917536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
43 Ye ZL, Huang Y, Li LF, Zhu HL, Gao HX, Liu H, Lv SQ, Xu ZH, Zheng LN, Liu T, Zhang JL, Jin HJ, Qian QJ. Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma. Acta Pharmacol Sin 2015;36:1237-45. [PMID: 25937637 DOI: 10.1038/aps.2015.18] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
44 Lee S, Kim JH, Lee JH, Lee JH, Han JK. Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging. Eur Radiol 2018;28:372-81. [DOI: 10.1007/s00330-017-4960-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
45 Feng Z, Li H, Zhao H, Jiang Y, Liu Q, Chen Q, Wang W, Rong P. Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma. Radiology 2021;300:219-29. [PMID: 33973839 DOI: 10.1148/radiol.2021203614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Gaba RC, Yap FY, Martinez EM, Li Y, Guzman G, Parvinian A, van Breemen RB, Kumar N. Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model. J Vasc Interv Radiol 2013;24:744-50. [PMID: 23510657 DOI: 10.1016/j.jvir.2013.01.488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
47 Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J, Fan W, Li Q, Wang Q, Zhong D, Miao X. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet. 2006;171:31-38. [PMID: 17074588 DOI: 10.1016/j.cancergencyto.2006.06.014] [Cited by in Crossref: 108] [Cited by in F6Publishing: 106] [Article Influence: 6.8] [Reference Citation Analysis]
48 Müller AM, Schmohl KA, Knoop K, Schug C, Urnauer S, Hagenhoff A, Clevert DA, Ingrisch M, Niess H, Carlsen J, Zach C, Wagner E, Bartenstein P, Nelson PJ, Spitzweg C. Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery. Oncotarget 2016;7:54795-810. [PMID: 27458162 DOI: 10.18632/oncotarget.10758] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
49 Chang ZY, Chen CC, Liu HM, Yeh YC, Lin TY, Lee TY, Huang TH. Positive Effects of Ger-Gen-Chyn-Lian-Tang on Cholestatic Liver Fibrosis in Bile Duct Ligation-Challenged Mice. Int J Mol Sci 2019;20:E4181. [PMID: 31455001 DOI: 10.3390/ijms20174181] [Reference Citation Analysis]
50 Lee D, Jang MK, Seo JH, Ryu SH, Kim JA, Chung YH. ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications. Exp Mol Med 2018;50:1-12. [PMID: 30054466 DOI: 10.1038/s12276-018-0106-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
51 Moon HE, Ahn MY, Park JA, Min KJ, Kwon YW, Kim KW. Negative regulation of hypoxia inducible factor-1alpha by necdin. FEBS Lett. 2005;579:3797-3801. [PMID: 15978586 DOI: 10.1016/j.febslet.2005.05.072] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
52 Lee JW, Park JA, Kim SH, Seo JH, Lim KJ, Jeong JW, Jeong CH, Chun KH, Lee SK, Kwon YG, Kim KW. Protein kinase C-delta regulates the stability of hypoxia-inducible factor-1 alpha under hypoxia. Cancer Sci 2007;98:1476-81. [PMID: 17608772 DOI: 10.1111/j.1349-7006.2007.00535.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
53 Guo DD, Xie KF, Luo XJ. Hypoxia-induced elevated NDRG1 mediates apoptosis through reprograming mitochondrial fission in HCC. Gene 2020;741:144552. [PMID: 32165297 DOI: 10.1016/j.gene.2020.144552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Zhou B, Ma R, Si W, Li S, Xu Y, Tu X, Wang Q. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett 2013;333:159-69. [PMID: 23352645 DOI: 10.1016/j.canlet.2013.01.028] [Cited by in Crossref: 132] [Cited by in F6Publishing: 123] [Article Influence: 14.7] [Reference Citation Analysis]
55 Sciarra A, Ronot M, Di Tommaso L, Raschioni C, Castera L, Belghiti J, Bedossa P, Vilgrain V, Roncalli M, Paradis V. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver Int. 2015;Epub ahead of print. [PMID: 25865109 DOI: 10.1111/liv.12844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
56 Shiraha H, Iwamuro M, Okada H. Hepatic Stellate Cells in Liver Tumor. Adv Exp Med Biol 2020;1234:43-56. [PMID: 32040854 DOI: 10.1007/978-3-030-37184-5_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
57 Deli G, Jin CH, Mu R, Yang S, Liang Y, Chen D, Makuuchi M. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2005; 11(7): 960-963 [PMID: 15742396 DOI: 10.3748/wjg.v11.i7.960] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
58 Yu Y, Zhang C, Liu L, Li X. Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas. Exp Ther Med 2013;5:761-6. [PMID: 23404440 DOI: 10.3892/etm.2012.873] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
59 Dai CX, Gao Q, Qiu SJ, Ju MJ, Cai MY, Xu YF, Zhou J, Zhang BH, Fan J. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 2009;9:418. [PMID: 19948069 DOI: 10.1186/1471-2407-9-418] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 6.1] [Reference Citation Analysis]
60 Liu K, Zhang X, Xu W, Chen J, Yu J, Gamble JR, McCaughan GW. Targeting the vasculature in hepatocellular carcinoma treatment: Starving vs normalizing blood supply.Clin Transl Gastroenterol. 2017;8:e98. [DOI: 10.1038/ctg.2017.28] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
61 Song Y, Cao L. N-myc downstream-regulated gene 1: Diverse and complicated functions in human hepatocellular carcinoma (Review). Oncol Lett 2013;6:1539-42. [PMID: 24260043 DOI: 10.3892/ol.2013.1636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
62 Chen JA, Shi M, Li JQ, Qian CN. Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol Int 2010;4:537-47. [PMID: 21063476 DOI: 10.1007/s12072-010-9192-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
63 Zhang M, Zhang W, Wu Z, Liu S, Sun L, Zhong Y, Zhang X, Kong X, Qian P, Zhang H, Lobie PE, Zhu T. Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma. Oncotarget 2016;7:3267-82. [PMID: 26675549 DOI: 10.18632/oncotarget.6572] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
64 Torimura T, Ueno T, Sata M. Liposome-mediated gene transfer of K1-5 suppresses tumor development and improves the prognosis of hepatocellular carcinoma in mice. Med Mol Morphol 2006;39:72-8. [DOI: 10.1007/s00795-006-0319-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
65 Wang SH, Chen LM, Yang WK, Lee JD. Increased extrinsic apoptotic pathway activity in patients with hepatocellular carcinoma following transarterial embolization. World J Gastroenterol 2011; 17(42): 4675-4681 [PMID: 22180709 DOI: 10.3748/wjg.v17.i42.4675] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
66 Lee D, Chung YH, Kim JA, Park WH, Jin YJ, Shim JH, Ryu SH, Jang MK, Yu E, Lee YJ. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. Cancer. 2013;119:2239-2246. [PMID: 23564564 DOI: 10.1002/cncr.28082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
67 Virmani S, Rhee TK, Ryu RK, Sato KT, Lewandowski RJ, Mulcahy MF, Kulik LM, Szolc-Kowalska B, Woloschak GE, Yang GY, Salem R, Larson AC, Omary RA. Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 2008;19:1483-9. [PMID: 18922400 DOI: 10.1016/j.jvir.2008.06.017] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]